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Abstract
Aim: To evaluate test-bolus versus bolus-tracking in the timing of hepatic arterial phase at contrast-enhanced magnetic resonance (MR) imaging in patients with 
hepatocellular carcinoma (HCC).
Methods: Eighteen patients with HCC were scanned by contrast-enhanced MR imaging with a delay time for the hepatic arterial phase calculated by test - bolus 
(n=9 patients) or bolus – tracking (n=9 patients). 
Results: Test-bolus and bolus-tracking techniques did not differ in SNR (301.2 ± 154.54 vs. 330.77 ± 240.75; P=0.89) and CNR (24.5 ± 18.74 vs. 19.24 ± 13.67; 
P=0.89).
Conclusions: Test - bolus vs bolus - tracking did not differ in the timing of hepatic arterial phase in patients with HCC.
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Introduction 
Hypervascularity on hepatic arterial phase after contast injection 
is one of the essential feature for the diagnosis of HCC according to 
the American Association for the Study of Liver Disease (ASL) [1] 
and the European Association for the study of the liver (EASL) [2] 
even though it is a transient phenomenon, and errors of only a few 
seconds during the image acquisition on hepatic arterial phase  may 
determine a reduced diagnostic confidence and accuracy. Anyway, the 
determination of the precise timing of optimal contrast enhancement 
for detection of hepatocellular carcinoma (HCC) is technically 
challenging because this timing is affected by the patient’s circulation, 
the contrast injection protocol, and the imaging protocol. 
Two methods - arbitrary fixed delay and test - bolus - have been 
used traditionally to determine the delay time from the start of 
contrast injection for the hepatic arterial phase at MR imaging. With 
the arbitrary fixed delay method, MR imaging is initiated 15–20 
seconds after the start of the injection. This technique does not take 
into account injection- or patient-related variables. More properly, 
with the test-bolus method, 1–2 mL of contrast medium are injected 
and simultaneous rapid and repetitive MR imaging at one level 
is performed during free breathing to determine the time to peak 
aortic enhancement. The delay time is calculated on the basis of the 
time of peak aortic enhancement, injection volume, and rate. While 
considered the most accurate, this method requires additional imaging 
and calculations. 
A further method corresponds to real-time bolus-tracking 
providing hepatic arterial phase images tailored to an individual 
patient’s cardiac output and peripheral bloodstream kinetic. A real time 
bolus-triggered method includes breath-hold instructions initiated 
as the contrast bolus  reaches  the  celiac  trunk (trigger point),  and 
imaging initiated at an 5–10 s delay from the trigger point. This method 
is very used despite it presents some dependence on the operator’s 
subjective assessment of the contrast arrival in the abdominal aorta.
To our knowledge, only few previous studies [3-5] have been 
conducted to evaluate the optimal acquisition delay for dynamic 
contrast-enhanced multiphase MR imaging of the liver and HCC even 
though no further study compared test - bolus and bolus - tracking 
techniques. 
The aim of this study was to evaluate test-bolus versus bolus-
tracking in the timing of hepatic arterial phase at contrast-enhanced 
MR imaging in patients with HCC.
Materials and methods
Patients
The institutional review board of our hospital approved this single-
centre prospective observational study. All patients provided informed 
content.
We included all patients who met the following inclusion criteria: 
biopsy-proven diagnosis of liver cirrhosis due to type B, type C, or 
alcoholic hepatitis; from one to four hypervascular nodules (diameter, 
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2-4cm; mean ± SD, 3.5 ± 1.2) suspected for HCC at contrast-enhanced 
CT and referred to contrast-enhanced abdominal MR imaging to 
improve the diagnostic confidence in the characterization of the 
dominant HCC nodule(s) or to identify additional nodules; no 
history of hepatic surgery or thermal ablation or chemoembolization; 
absence of renal failure (serum creatinine concentration < 1.5 mg/dL); 
contraindication to use of gadolinium-based contrast material. We 
initially included 25 patients while seven patients were excluded: three 
had tumor thrombi in the central portal vein, and four had numerous 
tumors involving the entire liver that may have changed hepatic 
hemodynamics. 
Thus the final study sample consisted in 18 patients (8 male and 
10 female; mean age, 66 years ± 12; body weight range, 33–69 kg; 
mean, 55.0 ± 8.4 [SD] kg). The age range of men was 48–88 years 
(mean, 67.5 years), and that of the women was 52–85 years (mean, 
71.0 years). The definitive diagnosis of HCC was based on histology 
(n=2), histopathologic evidence after hepatic surgery (n = 3), on 
imaging follow-up based on contrast-enhanced dynamic CT showing 
an increase in tumor size within 3 months (n = 2), or on typical 
enhancement pattern on contrast-enhanced MR imaging (n=11 
patients) based on EASL [1] or ASL criteria [2]. 
MR imaging
The MR imaging examination was performed within one month 
from contrast-enhanced CT using a superconducting magnet operating 
at 1.5 T (Achieva, 1,5T release 2.1.3.4, Philips Healthcare, Best, The 
Netherlands) with a peak gradient amplitude of 30 mT/m and a peak 
slew rate of 150 T/m/sec. Images were acquired in the transverse plane 
with a combined four-channel anteroposterior phased-array surface 
coil. Parallel imaging with a sensitivity-encoding (SENSE) technique 
with a factor of 1.5 – 1.7 was employed. A three-quarter field of view 
was used in the phase-encoding direction. Presaturation pulses were 
applied above and below the imaging volume to diminish flow artifacts.
The baseline MR imaging examination included a breath-hold fast 
spin-echo T2-weighted MR imaging sequence, a fat-suppressed T2-
weighted sequence, a T1-weighted in-phase and out-of-phase sequence, 
and a fast-field echo T2-weighted sequence. Dynamic MR imaging was 
performed before and after gadobenate dimeglumine (Gd-BOPTA, 0.1 
mmol/kg; 2 mL/sec) injection via a forearm or antecubital vein at 2 mL/
sec through a 18-gauge intravenous catheter employing an automated 
injector (Spectris MR Injector; Medrad, Indianola, Pa), followed by 
20 mL of saline at 2 mL/sec. Each dynamic contrast-enhanced MR 
imaging examination consisted in T1-weighted breath-hold resolution 
isotropic high volume (THRIVE) 3D with fat suppression MR 
sequences, with centric k-space acquisition, acquired before and after 
contrast administration at hepatic arterial, portal venous (70 seconds), 
equilibrium (3 minutes) and hepato-biliary phase (2 hours from the 
beginning of contrast injection). 
The delay time after i.v. contrast injection for the hepatic arterial 
phase was calculated by test - bolus in 9 patients by injecting 2 mL of 
contrast followed by 20 mL saline flush to determine the time to peak 
enhancement in the liver parenchyma according to the formula: ½ time 
of injection + time to the peak – ½ acquisition time + 4seconds. 
In the remaining 9 patients the delay time for the arterial phase was 
calculated by bolus – tracking technique. Between the precontrast and 
dynamic image acquisitions, an MR fluoroscopic sequence for contrast 
bolus chase (TR/TE, 4/0.87 msecs, flip angle 40°, slice thickness 80 mm, 
field-of-view 530 × 530 mm with a matrix of 256 × 128, acquisition time 
0.512 seconds) was performed, and yielded a subtracted coronal two-
dimensional projection of the abdominal aorta every second. Dynamic 
sequence on hepatic arterial phase began with 5 seconds delay after 
visualization of contrast at the abdominal aorta. Portal venous and 
equilibrium phase MR images were acquired with 70 seconds and 3 
minutes delay from the beginning of contrast injection while hepato-
biliary phase (HBP) MR images were acquired 2 hours from contrast 
agent injection.
Qualitative evaluation
To compare image quality between the hepatic arterial phase 
images acquired by the two techniques, two board-certified diagnostic 
radiologists with 22 and 11 years of experience in abdominal MR 
imaging performed independent visual assessments of image noise. 
They were blinded to clinical data and evaluated arterial and portal 
venous phase images without access to images obtained in other phases. 
After their independent evaluations, the reviewers assigned a score in 
consensus. Image noise was quantified on a 3-point scale on which 
a score of 3 denoted almost no or minimal image noise throughout 
the image; 2, a moderate degree of image noise that did not affect 
diagnostic utility, and 1, severe image noise that may severely hamper 
diagnostic utility. All readings were performed on a PACS– integrated 
workstation (19-inch TFT display, resolution 2560 × 1600 pixels, Ebit 
Sanità AET, Genoa, Italy) by using a proprietary software package (Ebit 
Sanità AET, Genoa, Italy). 
Quantitative analysis 
The same two readers, consensually, calculated the signal-to-
noise ratio (SNR = mean SI liver / SD) and contrast-to-noise ratio 
(CNR = mean SI lesion – mean SI liver/SD) by outlining freehand 
polygonal region of interest (ROIs) on the site of the hypervascular 
nodule and on the adjacent liver parenchyma within 2cm from the 
lesion on images acquired during the hepatic arterial phase by using 
a dedicated workstation (Extended WorkSpace eXplore, Philips, Best, 
The Netherlands). 
Statistical analysis
Statistical analysis was performed using STATA, version 13 
(StataCorp, Lakeway Drive, College Station, Texas, USA). We used 
the non-parametric correlation analysis and the intra-class correlation 
coefficient (ICC) to assess the agreement between test – bolus and 
bolus – tracking technique. Inter-observer agreement was considered 
as slight for an ICC of <0.21, fair for a value of 0.21–0.40, moderate for 
a value of 0.41–0.60, good for a value of 0.61–0.80, and optimal for a 
value of 0.81–1.00. 
For all tests a P value < .05 was considered to indicate a statistically 
significant difference.
Results
Tables 1 show the results of SNR and CNR of test - bolus and bolus 
- tracking techniques.
Test - bolus and bolus - tracking techniques did not differ in the 
estimation of the correct delay time for the hepatic arterial phase at 
contrast-enhanced MR imaging in patients with HCC in liver cirrhosis. 
There was good correlation (r=0.85) and agreement (ICC=0.9) between 
the delay times (25-27 seconds) for the hepatic arterial phase calculated 
by test – bolus and bolus – tracking techniques. Test – bolus versus 
bolus – tracking techniques did not differ both in SNR (301.2 ± 154.54 
vs. 330.77 ± 240.75; P=0.89 Mann-Whitney U test) and CNR (24.5 ± 
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18.74 vs. 19.24 ± 13.67; P=0.89).
Discussion
The first finding of our study was that test – bolus and bolus – tracking 
techniques did not differ in the estimation of the correct delay time for 
the hepatic arterial phase at contrast-enhanced MR imaging to visualize 
hypervascular HCC nodules in a background of liver cirrhosis. The test 
– bolus and bolus – tracking techniques present a good correlation and 
agreement for the timing of hepatic arterial phase. Bolus chase may be 
applied in the place of the bolus test, for those sequences with an early 
filling of the center of the K-space, to calculate the correct delay time 
for the hepatic arterial phase at contrast-enhanced MR imaging. This 
study shows evidence that accurate capture of liver arterial phase can 
be attributed mostly to the ability of real-time bolus tracking to resolve 
the strong variance in contrast arrival time into the aorta.
Theoretically, test - bolus technique provides the most accurate 
determination of the acquisition delay time for the hepatic arterial 
phase. The use of fluoroscopic triggering is appropriate only for MR 
sequences with which the high-contrast central portion of k-space is 
filled first, at the beginning of the acquisition, as in the present study. 
Contrary to the 3D THRIVE sequences with centric K-space acqusition 
used in this study, conventional 3D gradient-recalled echo sequences 
typically employ a sequential k-space acquisition with data acquired 
linearly or radially over many segments while the center of k-space is 
passed multiple times over the scan duration. As a consequence this 
averages the dynamic image contrast, such that the middle of the 
acquisition is representative of the peak contrast on the MR images. 
For these methods of K-space acquisition the test – bolus technique 
remains the most appropriate technique to be used in the calculation 
of the timing for the correct hepatic arterial phase in cirrhotic patients 
with HCC. 
The second finding of the present study was the absence of 
difference between the SNR and CNR of HCC between test – bolus 
and bolus – tracking techniques. This can allow to use undifferently 
the two timing techniques if centric K-space acquisition is employed in 
dynamic contrast-enhanced MR imaging. 
The main limitation of the present study is that an independent 
patient sample analysis was performed instead of paired data analysis 
with intra-individual comparison. 
In conclusion test - bolus vs. bolus - tracking did not differ in the 
timing of hepatic arterial phase in patients with HCC. 
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